A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs SA 237 (Primary)
  • Indications Neuromyelitis optica
  • Focus Registrational; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 31 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 31 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Jan 2017 Time frame of primary endpoint has been changed from up to approximately 27 months to up to approximately 38 months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top